Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation

The detection of circulating tumor DNA (ctDNA) in liquid biopsy samples as an oncological marker is being used in clinical trials at every step of clinical management. As ctDNA-based liquid biopsy kits are developed and used in clinics, companies work towards increased convenience, accuracy, and cos...

Descripción completa

Detalles Bibliográficos
Autores principales: Dao, Jonathan, Conway, Patrick J., Subramani, Baskaran, Meyyappan, Devi, Russell, Sammy, Mahadevan, Daruka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487653/
https://www.ncbi.nlm.nih.gov/pubmed/37686024
http://dx.doi.org/10.3390/ijms241713219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487653/
https://www.ncbi.nlm.nih.gov/pubmed/37686024
http://dx.doi.org/10.3390/ijms241713219

Ejemplares similares